<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740464</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-GCSF</org_study_id>
    <nct_id>NCT03740464</nct_id>
  </id_info>
  <brief_title>Long-acting G-CSF for Febrile Neutropenia</brief_title>
  <official_title>Long-acting Granulocyte Colony Stimulating Factor for the Prevention Febrile Neutropenia in Epithelial Ovarian Cancer: A Phase 3 Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze the effects of long-acting granulocyte colony stimulating factor
      (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are
      randomized into study group and control group. In study group, patients accept long-acting
      G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather
      than long-acting G-CSF. The primary end is the incidence of FN in every course of
      chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF
      and its expenses, visits to outpatient and emergency clinics, adverse events related to
      G-CSF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2018</start_date>
  <completion_date type="Anticipated">November 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>febrile neutropenia</measure>
    <time_frame>One year</time_frame>
    <description>the incidence of febrile neutropenia happened during each course of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>myelosuppression</measure>
    <time_frame>One year</time_frame>
    <description>the incidence of the incidence of febrile neutropenia happened during each course of chemotherapy happened during each course of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>doses of granulocyte colony stimulating factor</measure>
    <time_frame>One year</time_frame>
    <description>total doses of all granulocyte colony stimulating factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expenses of granulocyte colony stimulating factor</measure>
    <time_frame>One year</time_frame>
    <description>total expenses of all granulocyte colony stimulating factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visits to the hospital</measure>
    <time_frame>One years</time_frame>
    <description>visits to outpatient and emergency clinics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>One year</time_frame>
    <description>adverse events related to G-CSF according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Five years</time_frame>
    <description>progression-free survival after the primary treatment of ovarian cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">556</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Colony Stimulating Factors</condition>
  <condition>Febrile Neutropenia</condition>
  <condition>Myelosuppression Adult</condition>
  <condition>Adverse Event</condition>
  <condition>Cost-effectiveness</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>long-acting granulocyte colony stimulating factor</intervention_name>
    <description>A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>polyethylene glycol granulocyte colony stimulating factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Short-term granulocyte colony stimulating factor</intervention_name>
    <description>Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to accepted debulking surgeries and adjuvant chemotherapy

          -  Good performance status

          -  Aged 18 years or older

          -  Signed an approved informed consents

          -  No immunosuppressive disease

        Exclusion Criteria:

          -  Not meeting all of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>13911988831</phone>
    <phone_ext>86</phone_ext>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

